These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37013299)

  • 1. Biological composition, efficacy and primary efficacy endpoint of SARS-CoV-2 vaccines: A special communication.
    Ishaque I; Muhib M; Khalid Jamil OB
    J Pak Med Assoc; 2022 Nov; 72(11):2264-2269. PubMed ID: 37013299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A perspective on SARS-CoV-2 virus-like particles vaccines.
    Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
    Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.
    Wang F; Kream RM; Stefano GB
    Med Sci Monit; 2020 May; 26():e924700. PubMed ID: 32366816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
    De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC
    Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latest in COVID-19 Vaccine 'Candidates' Race.
    Atoum MF; Zreig DA; Abu Zreig LM
    Infect Disord Drug Targets; 2023; 23(1):e180822207640. PubMed ID: 35984031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines.
    Khoshnood S; Arshadi M; Akrami S; Koupaei M; Ghahramanpour H; Shariati A; Sadeghifard N; Heidary M
    J Clin Lab Anal; 2022 May; 36(5):e24418. PubMed ID: 35421266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
    Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
    Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
    Noor R
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
    Moore S; Hill EM; Dyson L; Tildesley MJ; Keeling MJ
    Nat Med; 2022 Nov; 28(11):2416-2423. PubMed ID: 36302894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena.
    Chavda VP; Bezbaruah R; Athalye M; Parikh PK; Chhipa AS; Patel S; Apostolopoulos V
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.
    Chauhan N; Soni S; Gupta A; Aslam M; Jain U
    J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Vaccine Development: Current Status.
    Poland GA; Ovsyannikova IG; Crooke SN; Kennedy RB
    Mayo Clin Proc; 2020 Oct; 95(10):2172-2188. PubMed ID: 33012348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.